Navigation Links
Peptimmune Presentations at Upcoming Events
Date:10/28/2008

immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Peptimmune Announces First Close of Series D Private Financing
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
4. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... 2013  Saddleback Memorial Medical Center in ... hospital on the West Coast to perform a hysterectomy ... provides women with a state-of-the-art, minimally invasive approach to ... , M.D., a highly regarded Orange ... of minimally invasive surgery at Saddleback Memorial, led the ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
(Date:5/23/2013)... , May 23, 2013 Pusan ... Inc., a private biotherapeutics and contract research company ... products for cancer, announced today a publication reporting ... treated with the oncolytic and immunotherapeutic vaccinia JX-594 ... research was published in the May 15 th ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... KVISTGAARD, Denmark, September 22 Bavarian,Nordic A/S ... European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO ... data from a Phase II double-blind, prospective randomized,placebo-controlled study ... Dr. Wayne Godfrey, Senior Medical Director, BN,ImmunoTherapeutics. , ...
... 22 Micromet, Inc. (Nasdaq: MITI ), a ... cancer, inflammation and autoimmune diseases, today announced the appointment of ... Medical Officer effective November 1, 2009. , ... and has more than 20 years of experience in clinical ...
... , SEATTLE, Sept. 22 Cell ... has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: ... prior to the market open on September 21, 2009. , ... modified market-capitalization weighted index designed to track the performance of the ...
Cached Biology Technology:New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 2Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 4Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index 2
(Date:5/24/2013)... in the ongoing public health debate is the lack ... nutrient dense. A new study, "Vegetable Cost Metrics ... Penny," published in the journal PLOS ONE , ... values in the produce aisle, providing one of the ... vegetables and delivering one of the most affordable source ...
(Date:5/24/2013)... studying noise in one French Quarter neighborhood of New ... municipal ordinances, Annette Hurley, PhD, Assistant Professor of Audiology ... Arriaga, a third-year LSUHSC doctor of audiology student, recommend ... hearing health. Their case study is published online in ... Management ., "An important part of an audiologist,s practice ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
Breaking Biology News(10 mins):New research shows that potatoes provide one of the best nutritional values per penny 2Please do try this at home 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... NY, April 29, 2011Videoscopy, a groundbreaking new ... Journal of Laparoendoscopic & Advanced Surgical ... Ann Liebert, Inc., publishers ( http://www.liebertpub.com ). ... surgical and microinvasive demonstrations of the latest ...
... team of scientists has produced an innovative new study of ... April issue of the journal Ecological Applications . ... both of UC Santa Barbara,s Department of Geography. They analyzed ... a study of 3,100 households in the cities of Minneapolis ...
... , , , , , , , ... , , , ... which is about one millisecond long. Several fish can be heard in... , ... , , , , , , ...
Cached Biology News:Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2UCSB urban ecosystem research featured in leading ecology journal 2UCSB urban ecosystem research featured in leading ecology journal 3Jump in communication skills led to species explosion in electric fishes 2Jump in communication skills led to species explosion in electric fishes 3Jump in communication skills led to species explosion in electric fishes 4Jump in communication skills led to species explosion in electric fishes 5Jump in communication skills led to species explosion in electric fishes 6Jump in communication skills led to species explosion in electric fishes 7
... cAMP - [125I] Direct SPA ... SPA.Includes lysis reagents that eliminate lengthy ... cAMP measurement (optional use).Range: 1.32-84.28 ng/ml ... pmol/ml).Overnight protocol.Store at 2-8 C. Category: ...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
...
Biology Products: